Archives
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
OSMI-1 Signal transduction through IL c FMS ligand
2019-10-01
Signal transduction through IL-34/ c-FMS ligand receptor also leads to the differentiation, survival and, angiogenesis, proliferation, adhesion and migration of cells of the monocyte/macrophage lineage similar to that of CSF-1 through the various pathways-First is through FAK (Focal Adhesion Kinase)
-
Compound A and Compound B Fig
2019-10-01
Compound A and Compound B (Fig. 4) were found in our in vitro screening assays and have similar CRF1 receptor in vitro profiles (Table 1). When binding was investigated using [125I]-CRF in ex vivo assay, Compound A inhibited binding of [125I]-CRF both in the frontal cortex and the pituitary; however
-
Nevertheless of the different types of
2019-10-01
Nevertheless, of the different types of scoring systems so far proposed, each of these [14], [29], [30] considered some aspects that could describe the fibrotic evolution, though none provided a quantitative assessment. Calvaruso et al. [8] showed that CPA had a better histological correlation with
-
Raloxifene is a second generation SERM that has tissue
2019-10-01
Raloxifene is a second generation SERM that has tissue-specific effects that differ from those of tamoxifen. Raloxifene was marketed for prevention and treatment of osteoporosis in postmenopausal women in the US and Europe. In a phase II randomized double-blind study, tamoxifen and raloxifene were e
-
Grapiprant is a selective antagonist for prostaglandin
2019-10-01
Grapiprant () is a selective antagonist for prostaglandin E (PGE) receptor subtype 4 (EP4) identified as a clinical candidate for the treatment of inflammatory pain associated with osteoarthritis (OA). It is currently under development for use in humans and dogs. The projected dosing regimen of grap
-
Another important new result that has
2019-10-01
Another important new result that has expanded the range of functions of iPLA2-VIA in physiology and pathophysiology is its implication in macrophage polarization under stimulation conditions. Ashley et al. [129] described in peritoneal macrophages from Pla2g6−/− mice that the absence of iPLA2-VIA f
-
br Oxidoreductase like MEM for
2019-10-01
Oxidoreductase-like MEM for prodrug activation Future outlook Although MEM-mediated prodrug activation has been performed by different MEMs and prodrugs, and their effectiveness have been proved in vivo, only a few types of MEMs or prodrugs have been explored in prodrug activation until now [2
-
Although enantioselective accumulation of metalaxyl
2019-10-01
Although enantioselective accumulation of metalaxyl in organisms is an integrated outcome of bio-process including absorption, transportation, and transformation, it is observed in our study that catalysis of CYP450 may lead to the enantioselective accumulation of metalaxyl. However, the mechanisms
-
Why are Tfh cell dynamics so fundamentally different
2019-10-01
Why are Tfh cell dynamics so fundamentally different in naive and immune animals? Initially, GC CGS 21680 HCl must pass stringent affinity and specificity checkpoints to ensure only high-affinity non-self-reactive cells are selected. Therefore, restricting primary Tfh cells with the greatest helper
-
The roles of ginsenoside in E and
2019-10-01
The roles of ginsenoside in E1 and 26S proteasome inhibition are shown in Table 2. The nitro substitute on the furan ring may be important for PYR-41 inhibition of the E1 enzyme (Yang et al., 2007). The macrocycle core and aliphatic tail of Largazole are responsible for inhibiting E1 activity (Unger
-
STO-609 acetate Compound was synthesized by the directed met
2019-10-01
Compound () was synthesized by the directed -metallation procedure (DOM) at the stage of the amide using butyl lithium and dry ice as CO source for the introduction of the carboxylic group. Thiophene amides were prepared from commercial 3-thiophenecarboxylic STO-609 acetate by conversion into the
-
Introduction Tumor necrosis factor TNF is a
2019-09-30
Introduction Tumor necrosis factor (TNF) is a pro-inflammatory mediator with the capacity to induce apoptosis (Benderska et al., 2012). Recent reports have shown that TNF might trigger cell death, at least in part, by directly affecting the reorganization of the Dihydroeponemycin cytoskeleton (Camp
-
increased The best preserved individuals were selected for
2019-09-30
The best preserved individuals were selected for isotope analysis of diet (Table 2). These represent 21 individuals including four subadults: two young children aged between 1.5 and 2.5 years old, one child between 7 and 11 years old and one adolescent (12–16 years old), and 17 adults including six
-
br Funding This work was
2019-09-30
Funding This work was supported by the Natural Science Foundations of China (81072327 and 81273114), Research Fund for the Doctoral Program of Higher Education of China (20103234110005), Key Program of Educational Commission of Jiangsu Province of China (11KJA330002), and a Project Funded by the
-
br Materials and methods br
2019-09-30
Materials and methods Results Discussion The main finding of the present study is that selective ETA and dual ETA/ETB receptor blockade markedly improve endothelium-dependent vasodilatation in patients with type 2 diabetes and vascular complications. The magnitude of improvement did not dif
15894 records 971/1060 page Previous Next First page 上5页 971972973974975 下5页 Last page